A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

Autor:	Akanksha Gupta, Eric W. Jacobson, Jonathan Haddad, George P. Vlasuk, Denise D Shortino, James G. Krueger, Craig L. Leonardi, Artemis Khacherian, Mayte Suárez-Fariñas, Lawrence C. Parish, Inna Cueto, Robert Matheson
Rok vydání:	2015
Předmět:	Adult Male medicine.medical_specialty Placebo-controlled study lcsh:Medicine Enzyme Activators Placebo Heterocyclic Compounds 2-Ring Gastroenterology law.invention Young Adult Double-Blind Method Sirtuin 1 Randomized controlled trial law Internal medicine Psoriasis Biopsy medicine Humans lcsh:Science Adverse effect Aged Multidisciplinary medicine.diagnostic_test business.industry lcsh:R Middle Aged medicine.disease Clinical trial Treatment Outcome Upper respiratory tract infection Immunology lcsh:Q Female business Research Article
Zdroj:	PLoS ONE PLoS ONE, Vol 10, Iss 11, p e0142081 (2015)
ISSN:	1932-6203
DOI:	10.1371/journal.pone.0142081
Popis:	UNLABELLED Activation of Sirtuin (silent mating type information regulation 2 homolog) 1, or SIRT1, is an unexplored therapeutic approach for treatment of inflammatory diseases. We randomized 40 patients with moderate-to-severe psoriasis (4:1) to three escalating doses of SRT2104, a selective activator of SIRT1, or placebo. Across all SRT2104 groups, 35% of patients (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b8db26e1e86b35a0f64f0950ffef6eb https://doi.org/10.1371/journal.pone.0142081 Zobrazit plný text záznamu